Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
NCT00090610
Completed
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/05/2015
Locations: Florida Gynecologic Oncology, Fort Myers, Florida +18 locations
Conditions: Ovarian Cancer
Register for Updates
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
NCT01209520
Completed
The trial investigates the feasibility and efficacy of targeting Non-Small Cell Lung Cancer (NSCLC) "driven" by epigenetic changes. The investigators study the impact of 5-azacitidine (Vidaza®, Celgene, Summit, NJ, USA) in combination with conventional cytotoxic chemotherapy in a sequential fashion. The study population consists of all NSCLC patients who undergo "curative" lung cancer resection and whose tumors harbor hypermethylation in any of the protocol-specific genes (samples will be banked... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2015
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Lung Cancer, Non Small Cell Lung Carcinoma, Hypermethylation
Register for Updates
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
NCT00479674
Completed
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. Monoclonal antibodies including bevacizumab target vascular endothelial growth factor (VEGF) to reduce angiogenesis. We hypothesize that the previously-untested c... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/29/2015
Locations: Presbyterian Health Care, Charlotte, North Carolina +3 locations
Conditions: Breast Cancer
Register for Updates
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
NCT00653939
Completed
The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients with chemotherapy naïve non-small cell lung cancer (NSCLC). This is a randomized parallel arm study. All participants will receive carboplatin, paclitaxel and bevacizumab, and half will additionally receive CA4P. Patients who complete the first 6 cycles of therapy and h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2015
Locations: Southbay Oncology Hematology, Campbell, California +14 locations
Conditions: Tumors
Register for Updates
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
NCT00151034
Completed
Purpose: The purpose of this study is to evaluate the efficacy and safety of treatment with trastuzumab (Herceptin) along with the three other chemotherapy drugs, paclitaxel, carboplatin and gemcitabine, in patients who have advanced urothelial cancer. This clinical trial will also collect information (alternative therapy, response rates, overall survival) from enrolled patients with HER2 negative tumors who are ineligible to receive study treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2015
Locations: California City of Hope National Medical Group, Duarte, California +10 locations
Conditions: Urologic Neoplasms
Register for Updates
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the Bladder
NCT00136175
Completed
This trial will evaluate the efficacy and safety of combination chemotherapy (paclitaxel, carboplatin, and gemcitabine) prior to surgery in the treatment of patients with locally advanced transitional cell cancer of the bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2015
Locations: The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Bladder Cancer
Register for Updates
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
NCT00352300
Completed
This phase I trial is studying the side effects of giving carboplatin and paclitaxel together with pegfilgrastim in treating patients with stage III or stage IV ovarian epithelial, fallopian tube, primary peritoneal, or carcinosarcoma cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony-stimulating factors, such as pegfilgrastim, may increase the numb... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/29/2014
Locations: University of California Medical Center At Irvine-Orange Campus, Orange, California +10 locations
Conditions: Fallopian Tube Carcinoma, Infectious Disorder, Neutropenia, Ovarian Carcinosarcoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Register for Updates
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00735696
Completed
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2014
Locations: ImClone Investigational Site, Beverly Hills, California +8 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
NCT00390611
Completed
This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to minimize the risk of bowel perforation.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/12/2014
Locations: Northeast Arkansas Clinic, Jonesboro, Arkansas +16 locations
Conditions: Ovarian Cancer
Register for Updates
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
NCT00821886
Completed
In this phase II trial the investigators propose to evaluate ixabepilone in combination with carboplatin and trastuzumab as neoadjuvant therapy in locally advanced breast cancer patients. Patients with early stage, HER2-positive breast cancer will receive six cycles of neoadjuvant treatment with ixabepilone, carboplatin, and trastuzumab every three weeks prior to surgery; after surgery, patients will continue treatment with trastuzumab every three weeks until week 52. Concomitant with the post-o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2014
Locations: Florida Cancer Specialists, Fort Myers, Florida +11 locations
Conditions: Breast Cancer
Register for Updates
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
NCT01207102
Terminated
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability. When combined with a taxane, platinum agents improve response in metastatic breast cancer, with carboplatin conferring less toxicity than cisplatin. The investigators hypothesize that the combination of weekly Abraxane® and carboplatin will lengthen time to progression without producing intolerable toxicity.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/08/2014
Locations: Duke University Medical Center, Durham, North Carolina +1 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer
NCT02013453
Withdrawn
The purpose of this study is to determine if the addition of proton pump inhibitors (PPIs) to standard chemotherapy can improve progression free survival in patients with head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2014
Locations: University of Michigan Hospital, Ann Arbor, Michigan
Conditions: Cancer of Head and Neck
Register for Updates